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SI Materials and Methods
Hierarchical Clustering of NAbs. NAbs were grouped into func-
tionally related clusters based upon their neutralization profiles as
previously described (1, 2). Neutralization profiles were com-
pared pairwise for all mAbs using Spearman correlation.
Spearman rho and P values were then used as input for hi-
erarchical clustering as implemented in the “pvclust” package
for R (cran.r-project.org/web/packages/pvclust/index.html) (3).
This clustering, depicted as a tree, was also used to order a
matrix of correlation values produced using the “corrplot” package
for R (cran.r-project.org/web/packages/corrplot/index.html) (4).
E1E2 Sequence Analysis. Evolutionary analyses were conducted in
MEGA7 (5). Diversity plots were generated using VarPlot v1.2
(6) (https://sray.med.som.jhmi.edu/SCRoftware/VarPlot/) with 1aa
steps and 20 aa windows. Inclusion of reference panel polymor-
phisms in the 11 and 19 HCVpp panels was calculated using a
previously described reference alignment from GenBank (7) and
the package “seqinr” in R, as previously described (2).
HCVpp Production and Neutralization. HCVpp were produced by
lipofectamine-mediated transfection of HCV E1E2, pNL4-3.Luc.
R-E-, and pAdVantage (Promega) plasmids into HEK293T cells
as previously described (2, 8, 9). Neutralization assays were per-
formed as described previously (10). Single concentrations or serial
dilutions of mAbs were incubated with HCVpp for 1 h at 37 °C
before addition to Hep3B cells in duplicate. Medium was changed
after 5 h, and cells were incubated for 72 h before measurement of
luciferase activity in cell lysates in relative light units (RLU).
Nonspecific human IgG (Sigma-Aldrich) at the same concentra-
tion as the NAbs was used as a negative control. Fraction un-
affected (fu) was calculated by the formula fu = RLUmAb/
RLUnonspecific IgG. Fraction affected was calculated by the formula
fa = 1 − fu. Percent neutralization was calculated by the formula
percent neutralization = fa × 100%. Neutralization by mAb serial
dilutions was plotted on median effect plots, with log10[mAb]
plotted against log10(fa/fu).
HCVcc Production and Neutralization. Generation of an HCVcc
chimera expressing the 1a53 E1E2 proteins was previously de-
scribed (11, 12). HCVcc neutralization assays were performed in
triplicate as previously described (11, 12). Briefly, HCVcc were
mixed with serially diluted mAbs, then incubated at 37 °C for 1 h.
Medium was removed from the cells and replaced with 50 μL of
HCVcc/antibody mixture. Medium was changed after overnight
incubation, and cells were incubated for another 48 h at 37 °C.
Cells were fixed with 4% formaldehyde, then stained for HCV
NS5A using primary anti-NS5A antibody 9E10 (a gift of Charles
Rice, The Rockefeller University, New York) at a 1:2,000 dilution,
then secondary antibody Alexa Daylight 488-conjugated goat anti-
mouse IgG (Life Technologies) at a 1:500 dilution. Images were
acquired and spot forming units were counted using an Auto-
immun Diagnostika (AID) iSpot Reader Spectrum operating AID
ELISpot Reader version 7.0. Percent neutralization was calculated
as 100% × [1 − (HCVccSFUmAb/HCVccSFUnonspecific IgG)].
Identification of Synergy/Additivity/Antagonism or Independence
Using the Loewe Additivity and Bliss Independence Models. For
four selected NAb combinations, two HCVpp were selected for
each NAb combination that were at least partially neutralized by
10 μg/mL of each NAb in that combination [fu < 0.3, except
HEPC3/1b14 (0.63), HEPC90/1a53 (0.65)]. The combination of
HEPC74/HEPC98 was also tested using 1a53 strain HCVcc.
Neutralization of HCVpp or HCVcc by serial dilutions of each
individual NAb was measured to determine 50% inhibitory con-
centrations (IC50). Neutralization by serial twofold dilutions of the
same NAbs, this time combined in a fixed ratio adjusted for their
relative IC50s, was then measured (13). Neutralization by serial
dilutions of individual component NAbs was simultaneously
measured, using the same antibody concentrations tested in the
NAb combination neutralization curve. The fu and fa values from
the individual NAb neutralization curves were used to calculate
neutralization for each NAb combination predicted by the
Loewe additivity and the Bliss independence models. Neutralization
predicted by the Loewe additivity model was calculated at each
antibody concentration using a script in Python (available at
https://github.com/mmankowski/Loewe-additivity-calculator) that
solves for the first 10 digits of fu1+2 in the equation
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with fu1 = fu of NAb1, fu2 = fu of NAb2, m1 = slope of the median
effect plot of NAb1, and m2 = slope of the median effect plot of
NAb2; m1 and m2 were calculated by linear regression of the
median effect plots of component NAb1 and component NAb2,
respectively, using Prism (Graphpad Software). For each NAb com-
bination, neutralization predicted by the Bliss independence model
was calculated at each antibody concentration using the equation
fu1+2 = fu1 × fu2.
Loewe additivity-predicted and Bliss independence-predicted
neutralization curves were plotted on median effect plots along with
the actual experimental NAb combination neutralization curves.
Quality Control for Loewe/Bliss Analysis. NAb combinations were
tested in at least two independent experiments against each of two
different HCVpp, except HC84.26/HC33.4, which was tested in two
experiments against only one strain. Neutralization by individual
NAbs and NAb combinations that were compared with each other
were measured in the same experiment against the same HCVpp or
HCVcc preparation. Only individual NAb curves with linear rela-
tionships onmedian effect plot withR squared of>0.85 were used to
calculate Loewe additivity and Bliss independence curves (Fig. S5).
The means of duplicate points were used to calculate both the R
squared and m. Lines were not required to pass through the point
(0,0). To confirm that NAbs were combined in optimal ratios to
allow discrimination between Loewe additivity and Bliss indepen-
dence, predicted Loewe and Bliss curves for each combination were
confirmed to be statistically different from each other for at least
three antibody concentrations (Fig. S5). NAb concentrations at
which either model predicted fu < 0.001 were removed from the
experimental vs. Bliss/Loewe comparison, as values this low are
outside of the reliable dynamic range of the neutralization assay.
Binding Competition Assays. MAb binding to E1E2 was quanti-
tated using ELISA as previously described (14).† Blocking NAbs
†Netski DM, et al., 11th International Symposium on Hepatitis C Virus and Related Viruses,
October 3−7, 2004, Heidelberg, Germany.
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were added first after dilution to either 50 μg/mL (HC84.26,
HEPC90/1a142 E1E2) or 20 μg/mL (all other NAbs). Binding
NAbs, which had been biotinylated using an EZ-Link NHS-
PEG4-Biotin and Labeling Kit (Thermo Fisher Scientific),
were added at their EC75 (as previously determined using serial
dilution binding assays), followed by streptavidin−horseradish
peroxidase, and tetramethylbenzidine peroxidase substrate. For
HEPC74/HEPC98 binding competition curves, the same pro-
tocol was used, but serial fivefold dilutions of both blocking and
binding NAb, starting at 50 μg/mL, were used.
Timecourse Inhibition Experiments. Strain 1a154 HCVpp were incu-
bated with HEPC74 at 50 μg/mL or HEPC98 at 5 μg/mL (T-30-min
condition), or medium alone for 30 min at 37 °C, chilled to 4 °C,
then added to hep3B cells that had been prechilled to 4 °C. For
T-30-min condition, CL58 peptide (15), anti-CD81 mAb (BD
555675), anti−SR-B1 mAb (BD 610882), or isotype control mAb
(BD 560550) at 50 μg/mL concentration was incubated with hep-
atoma cells for 30 min, then removed before HCVpp addition.
HCVpp were then incubated with cells for 4 h at 4 °C to allow
particle attachment without entry. Cells were then washed to
remove unattached virus, and cells moved to 37 °C, to allow viral
entry. Inhibitors were then added immediately (T0m), after
30 min, 60 min, or 120 min. In each case, inhibitors were incubated
with the cells for 30 min total, before washing to remove the in-
hibitor. Cells were then incubated for 72 h before quantitation of
luciferase activity. Percent inhibition was calculated relative to
infection of virus absent any inhibitor. Background inhibition was
subtracted, and maximal inhibition of each inhibitor was adjusted
to 100% to facilitate comparison.
Expression of sE2.A truncated, soluble form of strain 1a154 (H77)
E2 ectodomain (sE2), encompassing residues 384 to 645, as
previously described (16), was cloned into a mammalian expression
vector (phCMV3_Ig Kappa_HIS, a gift of Leopold Kong, The
Scripps Research Institute, La Jolla, CA). The sE2 construct was
cotransfected with pAdvantage (Promega) into HEK293T cells.
Supernatant was collected at 48 and 72 h, passed through a 0.2-μm
filter, and concentrated using a regenerated cellulose centrifugal
filter with a 10-kDa cutoff (Amicon). Unpurified supernatants
were used for heparan binding experiments and ELISA. The sE2
protein used for CHO binding experiments was expressed by
transient transfection into HEK293-6E cells. The sE2 was pu-
rified from filtered cell supernatants using nickel-nitrilotri-
acetic acid (GE Healthcare) affinity chromatography and
purified further by size exclusion chromatography on a Superdex
200 Increase 10/300 column (GE Healthcare) in 20 mM Tris pH 7.4,
150 mM NaCl.
sE2 Binding to CHO Cells. CHO−CD81 and CHO−SR-B1 binding
experiments were carried out as previously described (17, 18).
CHO cells expressing recombinant human CD81 or SR-B1 were
detached using PBS supplemented with 4 mM EDTA and 10%
FBS, incubated with sE2, then 0.5 μg of mouse anti-6x His-tag
antibody, then Alexa Fluor 647-labeled goat anti-mouse IgG
secondary antibody, then fixed with 1% paraformaldehyde and
analyzed on an LSRII cytometer (Becton-Dickinson) using
FlowJo software (Tree Star). For mAb binding inhibition ex-
periments, sE2 was preincubated with serial dilutions of mAbs or
nonspecific human IgG, then used to stain CHO cells as above.
sE2 Binding to Heparan Sulfate.Heparan binding experiments were
carried out essentially as previously described (19). Briefly, strain
1a154 sE2 was incubated with serial dilutions of HEPC74,
HEPC98, or nonspecific human IgG, then added to ELISA wells
that had been coated with 1 μg of heparan sulfate (Sigma). All
proteins were diluted in blocking buffer (0.05% Tween 20, 3%
BSA in PBS). The sE2 binding was detected with mouse anti-6x
His-tag antibody and goat-anti mouse-HRP antibody (Abcam).
Background binding to wells without heparan was subtracted.
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Fig. S1. Selection of a diverse and representative genotype 1 HCVpp panel. (A) Comparison of neutralizing breadth of 32 mAbs determined using a previously
described diverse panel of 19 genotype 1 HCVpp (1, 2, 3), and the 11 HCVpp subset of that panel used in the current study. Each point indicates the neutralizing
breadth of a single mAb. P = not significant (ns) by paired, two-sided t test. (B) Neighbor-joining tree of E1E2 amino acid sequences of 634 genotype 1a and 1b
reference sequences from GenBank (4) and the 11 HCVpp used in this study (red circles), with distances computed using the JTT method. The tree is drawn to
scale, with branch lengths measured in the number of substitutions per site. Evolutionary analyses were conducted in MEGA7 (5). (C) Diversity plot comparing
variability at each E1E2 amino acid position of the reference panel of 634 genotype 1 sequences (black), the 19 HCVpp panel (blue), and the 11 HCVpp panel
(red). (D) Percentage of amino acid polymorphisms that are present with at least 10% frequency in the 634 sequence reference set that are found in the
reference sequence set (black), the 19 HCVpp panel (blue), and the 11 HCVpp panel (red).
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Fig. S2. Neutralization profiles of the NAb combinations not shown in Fig. 3. Values are mean percent neutralization by 10 μg/mL of each individual NAb or
10 μg/mL total concentration of NAb combinations, measured in duplicate. Pink indicates NAb/HCVpp tests with percent neutralization >50%. Arrows indicate
complementary neutralization by the two NAbs in each combination.
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Fig. S3. Additional independent experiments assessing HEPC3/HEPC74, HEPC3/HEPC90, HC84.26/HC33.4, and HEPC74/HEPC98 neutralizing synergy, additivity, antagonism, or independence (related to Figs. 5 and 6). Each
graph represents an independent experiment. Median effect plots compare experimental inhibition (blue) to the inhibition predicted by either the Loewe additivity (red) or Bliss independence (orange) models. Statistically
significant differences between the experimental inhibition and Loewe or Bliss predictions are indicated with red and orange asterisks, respectively. Experimental neutralization values are the means of duplicate mea-
surements. Loewe and Bliss values are the means of four individual predictions made at each antibody concentration using data from individual NAb neutralization, which was measured in duplicate. Error bars indicate SDs.
*P < 0.05 by paired t tests, corrected for multiple comparisons using the Holm−Sidak method. The (A) 1a53 HCVpp or (B) 1b14 HCVpp neutralized by HEPC3/74; (C) 1a142 HCVpp or (D) 1a53 HCVpp neutralized by HEPC3/
HEPC90; (E) 1a38 HCVpp neutralized by HC84.26/HC33.4; and (F) 1a53 HCVpp or (G) 1a154 HCVpp neutralized by HEPC74/HEPC98.
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Fig. S4. Controls for sE2 binding to CD81−CHO or SR-B1−CHO cells. (A) ELISA binding of HEPC74 and HEPC98 to strain 1a154 sE2. (B) Binding of serial dilutions
of 1a154 (H77) sE2 to CD81-expressing or SR-B1-expressing CHO cells. Each point was calculated from 10e4 events. Background binding to wild-type CHO cells
was subtracted from MFI values.
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Fig. S5. Quality control for Loewe/Bliss analysis. Comparison of Loewe-predicted (red) and Bliss-predicted (orange) curves for each NAb combination ex-
periment. Each graph represents an independent experiment. Error bars indicate SDs. To confirm that NAbs were combined in optimal ratios to allow dis-
crimination between Loewe additivity and Bliss independence, predicted Loewe and Bliss curves for each combination were confirmed to be statistically
different from each other at a minimum of three antibody concentrations. *P < 0.05 by paired t tests, corrected for multiple comparisons using the Holm−Sidak
method. Values shown are R-squared values, calculated by linear regression, for each individual NAb neutralization curve used to calculate the Loewe and Bliss
curves. Only individual NAb curves with linear relationships on median effect plots with R squared of >0.85 were used to calculate Loewe additivity and Bliss
independence curves. (A) HEPC3/HEPC74, 1a53 HCVpp experiments. (B) HEPC3/HEPC74, 1b14 HCVpp experiments. (C) HEPC3/HEPC90, 1a142 HCVpp experi-
ments. (D) HEPC3/HEPC90, 1a53 HCVpp experiments. (E) HC84.26/HC33.4, 1a38 HCVpp experiments. (F) HEPC74/HEPC98, 1a53 HCVpp experiments. (G) HEPC74/
HEPC98, 1a53 HCVcc experiment. (H) HEPC74/HEPC98, 1a154 HCVpp experiments.
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Table S1. NAbs analyzed
mAb Antigenic domains Critical binding residues by alanine scanning* Refs.
CBH-5 Domain B 412, 416, 417, 418, 420, 421, 422, 423, 483, 484, 485, 488, 523, 525, 527, 530,
533, 535, 538, 540, 550
1, 2
HC84.26 Domain D 429, 441, 442, 446, 616 3
HEPC3 Antigenic region 3/domain B 425, 427, 428, 437, 499, 520, 530, 535 4
HEPC74 Antigenic region 3/domain B 425, 428, 436, 437, 530, 535 4
AR3C Antigenic region 3/domain B 424, 488, 523, 525, 530, 535, 538, 540 5
AR3B Antigenic region 3/domain B 412, 416, 418, 423, 424, 523, 525, 530, 535, 540 5
HEPC46 Antigenic region 1 541, 542, 543, 544, 545, 546, 548, 549, 594, 598, 633 4
HEPC98 HVR1 402, 405, 408 4
HC33.4 Epitope “1” 408, 413, 418, 420 6
7
AR5A Antigenic region 5 201, 204, 205, 206, 639, 657, 658, 665, 692 8
AR4A Antigenic region 4 201, 204, 205, 206, 487, 657, 658, 692, 698 8
HEPC90 NA NA 4
NA, not available.
*Residue numbering is based on polyprotein position. Mutation of critical binding residues reported for HC84.26, HC33.4 to alanine reduce mAb binding by at
least 60%. Mutation of critical binding residues reported for the remaining mAbs reduce binding by at least 50%.
1. Hadlock KG, et al. (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:
10407–10416.
2. Owsianka AM, et al. (2008) Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89:653–659.
3. Keck ZY, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS
Pathog 8:e1002653.
4. Bailey JR, et al. (2017) Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight 2:92872.
5. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25–27.
6. Keck Z, et al. (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.
J Virol 87:37–51.
7. Keck ZY, et al. (2016) Antibody response to hypervariable region 1 interferes with broadly neutralizing antibodies to hepatitis C virus. J Virol 90:3112–3122.
8. Giang E, et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109:6205–6210.
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